Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2015 Jan;65(1):54–61. doi: 10.1097/FJC.0000000000000163

Figure 3.

Figure 3

A & B. Effects of erlotinib with or without aprepitant treatment for 9 weeks on rat (A) neutrophil basal superoxide generating activity, and (B) plasma 8-isoprostane content. Blood was sampled from rats treated with erlotinib (starting 10 mg/kg/day, oral) and/or aprepitant (starting 2 mg/kg/day, oral) at 9 weeks of exposure. (A) circulating neutrophil basal superoxide generating activity was determined as SOD-inhibitable reduction of cytochrome c; and (B) plasma 8-isoprostane was assessed by a colorimetric ELISA kit. Values for erlotinib ± aprepitant rats were compared to time-matched controls, and are means ± SEM of 4-6 rats per group. ** p < 0.01 versus control; ++ p < 0.01 versus erlotinib alone.